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Abstract
Major depressive disorder (MOD) is a disease often underdiagnosed in adolescents. For adolescents in particular, MOD
can have far-reaching implications on developmental, social
and emotional functioning. Unfortunately, few guidelines
detail consistent means by which to evaluate and treat these
patients; significantly more information exists that solely
pertains to the adult population. Governing bodies such as
the American Academy of Child and Adolescent Psychiatry
(AACAP) and Resource for Advancing Children's Health
(REACH) recommend that primary care physicians be diligent in their psychiatric analyses and follow-ups with young
patients who may be experiencing MOD. Both psychotherapy
and medications, either as monotherapy or in combination,
should be considered when treating MOD. Selective serotonin reuptake inhibitors (SSRis), particularly fluoxetine, are
considered the anti-depressants of choice despite their black
box warning pertaining to increased suicidality in children
and adolescents. In all cases, benefits of therapy should always be assessed alongside potential risks. Pharmacists can
play a significant role in counseling patients on these potential risks and benefits for both the pharmacological and nonpharmacologic aspects of MOD treatment
Introduction
Major depressive disorder (MOD) is a debilitating disease
that greatly affects adolescents, particularly when left
untreated. The World Health Organization (WHO) defines
adolescence as the growth period between childhood and
adulthood when individuals are between the ages of 10 to
19.1 Major depressive disorder is common in this age group
with 11.2 percent of American adolescents suffering from
MOD or dysthymic disorder.2 Dysthymic disorder is a milder
form of depression that occurs for at least two years (Table
1).3 The average length of a depressive episode ranges from
two to eight months. The recurrence rate of MOD is anywhere from 20 to 60 percent one to two years after remission, but increases to 70 percent after five years.4 Although
adolescents and adults can both be diagnosed with MOD,
adolescents exhibit different signs and symptoms than their
adult counterparts.s Adolescents may feel physically sick, get
into trouble or perform poorly at school, become increasingly irritated or feel misunderstood.S In addition, they may
become socially withdrawn or suffer from substance abuse.6
Comparatively, adults may complain of feeling sad, fatigued,
or frustrated and may struggle with activities of everyday
life.7
Major depressive disorder is a complex and disabling disease
that can negatively impact all aspects of a patient's life: deJune 2014 Volume 5, Issue 2

velopmentally, socially and emotionally.6.8 Any patient suffering from MOD, regardless of age, needs to be treated with
medication, psychotherapy or a combination of the two. Like
adults with MOD, adolescents are at an increased risk for
suicide if their depression becomes too severe.6 Depressed
adolescents are at an even greater risk than depressed adults
for completing suicide, which is the third leading cause of
death in American adolescents 15 to 19 years of age. 9 In addition to the increased risk of suicide, untreated MOD has
long-term social and clinical implications. Adolescents who
suffer from milder forms of depression, such as dysthymic
disorder, may eventually meet the criteria for MOD as adults
if their condition is left untreated.6 Unfortunately, MOD is
often underdiagnosed in this young patient population because they often do not fully meet the diagnostic criteria.6
Diagnosis may also be complicated by the existence of comorbid conditions such as anxiety and learning/conduct disorders.10 Patients who show signs and symptoms of MOD
should receive proper diagnosis, psychiatric interventions
and adequate therapeutic treatment based on their age and
disease severity.6 Although MOD affects a significant number
of adolescents, there is variability between existing diagnostic and treatment guidelines, few medications are currently
indicated for MOD treatment in adolescents, and limited research exists in this patient population.11

Guidelines for Diagnosis and Treatment
There are a variety of guidelines available for the treatment
of MOD in adolescents; however, these documents are inconsistent. Recommendations regarding medication use, psychotherapy and the duration of these therapies vary. The length
of psychotherapy and duration of medication use depend on
the severity of a patient's MOD. Unfortunately, there are no
studies available in adolescents with information regarding
which patients should receive therapy past the usual recommendations.8 Currently, fluoxetine and escitalopram are the
only antidepressants approved by the U.S. Food and Drug
Administration (FDA) for use in adolescents with MDo.11
Guidelines and treatment recommendations are currently
available from the American Academy of Child and Adolescent Psychiatry (AACAP) and the Resource for Advancing
Children's Health (REACH). The AACAP is a non-profit association whose members aim to treat and improve the quality
of life in children and adolescents who suffer from mental
health disorders. They provide treatment parameters for a
variety of mental health disorders, including MDo.12 The
AACAP published their MOD parameters, which are based on
the 4th edition of the Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV), in 2007.8 Guidelines for Adoles-
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cent Depression in Primary Care (GLAD-PC) by REACH were
also released in 2007. The GLAD-PC, a North American collaborative, was specifically developed for primary care physicians (PCPs) due to the differences between primary care
and specialty care settings. The GLAD-PC: I discuss guidelines
for the identification, assessment, and initial management of
depression in youth ages 10 through 21. The GLAD-PC : II
then outlines the treatment and ongoing management of adolescent depression. Few adolescents with MDD are actually
seen by mental health professionals and instead seek help
from their PCPs. The GLAD -PC helps PCPs, who may not be
familiar with treating MDD in adolescents, properly diagnose
and treatthese patients.13
AACAP Practice Parameters for the Assessment and
Treatment of Children and Adolescents with Depressive
Disorders
The AACAP states that depression is a spectrum disorder
that ranges from subsyndromal to syndromal. To be diagnosed with a syndromal disorder, adolescents must have a
change in mood with either a depressed/irritable mood or a

loss of interest/pleasure that accompanies a group of other
symptoms for at least two weeks. These other symptoms
include wishing to be dead, suicidal thoughts/attempts,
changes in appetite or sleep and either decreased energy,
concentration or self-worth. Although AACAP's diagnostic
guidelines were based on DSM-IV, they are still similar to the
recommendations in DSM-V (Table 1).3.a The AACAP recommends that physicians develop a relationship with their patient, his or her family, school personnel and other health
care providers. The academy also suggests that physicians
screen young patients at regular office visits to identify depressive disorders. If screening suggests the patient may be
suffering from a depressive disorder, further evaluation is
warranted including an assessment about harm to the patient or others. Additionally, this evaluation should include a
family history of depressive disorders, ongoing or past negative events, such as abuse or divorce of parents and available
support for the patient.B
Treatment with medication should always include an acute
and continuation phase. Maintenance treatment may also be

Table 1. Adapted from the DSM-V. 3
DSM-V Diagnostic Criteria for MDD in Adults and Adolescents

A patient must have at least five of the following symptoms occurring during the same twoweek period and represent a change from previous functioning. One of the symptoms must
either be depressed mood OR loss of interest/pleasure.
1) Depressed mood most of the day nearly every day.

Criteria A

32

2) Marked decrease in interest/pleasure most of the day nearly every day.
3) Significant weight loss or gain (5% of body weight in a month) or decrease in appetite nearly
every day.
4) Insomnia or hypersomnia nearly every day.
5) Psychomotor agitation or retardation nearly every day (observed by others).
6) Fatigue or loss of energy nearly every day.
7) Feelings of worthlessness or excessive/inappropriate guilt nearly every day.
8) Diminished ability to think or concentrate or indecisiveness nearly every day.
9) Recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide
attempt or a specific plan.

Criteria B

Symptoms cause clinically significant distress/impairment in social, occupational, or other aspects of life.

Criteria C

Episode not attributed to physiological effects of substance abuse or another medical condition.

Criteria D

The occurrence of the major depressive episode cannot be explained by schizophrenia or a
schizophrenia-like illness or another psychotic disorder.

Criteria E

There has never been a manic or hypomanic episode.
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appropriate in some patients. Treatment during the acute
phase is to help relieve symptoms, while continuation treatment is to prevent relapse and to strengthen the acute phase.
Maintenance therapy is recommended for patients who have
a more severe or chronic disorder to prevent recurrence.
Treatment at every stage should include patient and caregiver education on MOD, supportive management, and family /school involvement. Both parents and patients should be
a part of the decision-making process for treatment. Adolescents with uncomplicated or brief depressive symptoms can
often be successfully treated with education, case management and supportive care (psychotherapy) for four to six
weeks. Patients who have a limited response to nonpharmacologic therapy or those with more severe depression may
require both psychotherapy and antidepressant medications.
The AACAP defines response to treatment as having no
symptoms or having a significant reduction in depressive
symptoms for at least two weeks.a Both psychotherapy and
antidepressants can be used as monotherapy. Research attempting to prove a benefit exists in patients using combination therapy has been inconclusive.14 However, clinicians
state that patients do respond better to combination therapy;
therefore, AACAP suggests patients receive both psychotherapy and medications, especially if they have moderate to severe or refractory MOD. The AACAP recommends patients
use fluoxetine because it is indicated for use in adolescents
(Note: these guidelines were published before escitalopram
was an indicated therapy). Studies with selective serotonin
reuptake inhibitors (SSRis) other than fluoxetine had not
shown a significant difference in treatment response compared to placebo when these guidelines were written.a
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as their chief complaint. Assessment should include direct
interviews with the patient as well as family members or
caregivers. The GLAD-PC also recommends diagnosis of depression based on the diagnostic criteria described in DSMIV or in International Classification of Diseases, 10th Revision
(ICD-10). During initial management, the PCP should educate
the patient and family members about depression and its
symptoms. A treatment plan should be established and goals
should be set individually for key areas of function for the
patient: home, school and peer settings. All management
must include a safety plan that establishes an emergency
contact in case of increased suicidality or crisis-type situations resulting from the depressive symptoms or treatment.
The GLAD-PC notes that a safety plan should be established
early because safety concerns are highest during diagnosis
and initial management. The PCP should involve a concerned
third party, such as a school nurse or other adult that can
provide adequate support and supervision. Jt is also recommended that all materials that could cause serious harm or
death be removed as a measure ofprecaution.1s

The doses of SSRis used in adolescents are similar to adult
dosages. Low doses should be given initially and then titrated
up to the lowest effective dose. Prescribing physicians should
reassess the patients every four weeks and adjust doses
when necessary. It is recommended that patients be treated
for six to 12 months to avoid relapse. Physicians should also
evaluate their patients to see if they are candidates for longer
use; candidates include those with severe or refractory
depression. Somatic treatments, such as electroconvulsive
therapy or transcranial magnetic stimulation, in addition to
pharmacotherapy and psychotherapy, may be necessary in
patients with psychosis, seasonal depression or bipolar disorder. Moreover, comorbid psychological and physiological
conditions should also be appropriately treated.B

According to GLAD-PC: II, the PCP should provide a six to
eight week period of active support and monitoring for patients diagnosed with mild depression before making a treatment recommendation. The PCP should monitor patients
every one to two weeks through follow-up phone calls in addition to frequent office visits. The PCP can provide support
by making recommendations for exercise or leisure activities, peer support groups and patient self-management goals.
Educational materials should also be provided to the patients
and their families at this time.16 If patients continue to present with symptoms, treatment with an SSRI antidepressant
or psychotherapy should then be recommended. Fluoxetine
is considered first-line treatment for all adolescents ages 10
through 21. Escitalopram is considered first-line treatment
for adolescents ages 12 through 21.16 Immediate treatment is
recommended for adolescents with moderate to severe depression. Additionally, consultation with a mental health specialist should be considered in cases of adolescents with
moderate/severe depression, coexisting substance abuse or
psychosis. If a referral is made, the roles and responsibilities
of both the PCP and mental health clinician need to be discussed and agreed upon by the involved clinicians, the patient and the patient's parents/guardian. It is important to
note that the PCP should continue to follow-up with the adolescent after the referral.17

Guidelines for Adolescent Depression in Primary Care
The recommendations from the GLAD-PC: I state that the
PCP identifies adolescent patients who are at risk for depression and systematically monitor them for the development of
a depressive disorder. The PCP should specifically assess
psychosocial function in adolescent patients, as altered function can be an early sign of depression. Risk factors include
personal or family history of psychiatric illness, substance
abuse and suicidal behavior. Adolescents under psychosocial
stress due to abuse, neglect or other traumatic events are
also considered at increased risk for depression. To assess
and diagnose patients, the PCP should evaluate both highrisk patients and patients who describe emotional problems

The guidelines note that appropriate psychotherapy methods
include cognitive behavioral therapy (CBT) and interpersonal therapy (IPT). Cognitive behavioral therapy focuses on
the patient's thoughts and behaviors to improve their mood.
Parents or caregivers may be included in sessions of CBT.
Key components of this therapy include incorporation of
pleasurable behavior, reducing negative thoughts, and decreasing feelings of hopelessness by improving problemsolving skills. IPT focuses on interpersonal problems that
may act to either cause or worsen depression. Goals of therapy include addressing specific interpersonal problems while
improving interpersonal problem-solving skills and communication skills. 18 Parents and caregivers are invited to partici-
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pate during specific phases of IPT, including the first session,
during the middle phase of treatment and at the end of treatment.17,18
The PCP should reassess diagnosis and initial course of treatment if no improvement is seen within six to eight weeks of
treatment for moderate to severe depression. Additionally, a
mental health consultation should be reconsidered if there is
no improvement noted after initial treatment or only partial
improvement is seen after all primary care therapeutic approaches have been attempted. A reduction in symptoms of
depression, improved ability to function and reports of improvement by the patient or parent/caregiver are all considered indicative of improvement. Several diagnostic aids in
addition to DSM-IV and ICD-10 are mentioned in the GLADPC toolkit that can assist in reassessing patients and quantifying a reduction in symptoms. The Columbia Depression
Scale-Teen Version is a survey that consists of yes or no
type questions and incorporates inquiries about suicide ideation and attempts. The scale is based on a point system
where "yes" is worth one point and "no" is worth zero points.
There are two versions of the survey-one for parents and
one for the adolescent. The scores are then assigned to the
chance of depression, ranging from very unlikely to highly
likely. In addition, the six question Kutcher Adolescent Depression Scale (KADS) is scored to indicate if a patient is
"possibly depressed" or "probably not depressed." Moreover,
a modified version of the Patient Health Questionnaire, 9th
Revision (PHQ-9) is available to assess adolescent depression (note: research has not been conducted to validate the
modifications). Modified PHQ-9 consists of a survey format
that incorporates the frequency of symptoms (i.e. "not at all"
through "nearly every day"). Points are assigned to the patient's responses that rank the severity of depression from
mild to severe.16
After reassessing the patient, the PCP should address the
choice and efficacy of initial treatment. If the patient does not
respond to the maximum therapeutic dose of an SSRI antidepressant, treatment with a different SSRI antidepressant
should be considered. The GLAD-PC toolkit for PCPs includes
SSR!s not FDA-approved for adolescents (i.e. sertraline, citalopram, fluvoxamine, paroxetine) as alternatives.16 If only
psychotherapy or only antidepressant therapy was initially
utilized, the clinician should consider adding the other therapy to the patient's treatment plan.17 If the patient fails two
trials of treatment with an SSRI and a course of CBT or !PT,
the PCP should consult a mental health specialist to recommend a second-line medication such as citalopram or sertraline. If a patient fails a third medication trial, the PCP
should reevaluate their diagnosis and consider a combination of medications.16 Increasing the initial SSRI antidepressant dose above FDA-approved ranges is also suggested as a
possible consideration for patients who only partially respond to therapy. The guidelines do not specify if this is a
last-line option, but recommend that the dose be increased in
consultation with a mental health professional. Assessments
should include the presence of comorbid conditions such as
substance abuse or bipolar symptoms that may affect
treatment.17
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According to GLAD-PC, ongoing management should include
the tracking of goals and treatment outcomes. Goals of treatment include both an improved ability to function and cessation of depressive symptoms. Moreover, the patient's level of
function should be assessed in various environments (i.e.
home, school, and peer settings). Patients should be seen
within one week of beginning treatment to initiate such
tracking. Both GLAD-PC and AACAP experts recommend that
antidepressant therapy should be continued for six to 12
months after complete resolution of depressive symptoms.
The GLAD-PC cites AACAP in the recommendation that patients may be monitored for up to two years if patients suffer
from recurrent depressive episodes.0.1 7 If treatment includes
an SSRI antidepressant, the PCP should monitor the patient
for adverse events. The GLAD-PC references the FDA's recommendation for monitoring children and adolescents using
antidepressants for clinical worsening, suicide risk and
changes in behavior. These guidelines note that the optimal
frequency of monitoring is controversial.17

Pharmacological Treatment Options
Selective serotonin reuptake inhibitors are most commonly
prescribed to treat depressive disorders due to their effectiveness over older generations of antidepressants such as
the tricyclic antidepressants (TCAs). SSRis directly inhibit
the adenosine triphosphate (ATP) dependent carrier in presynaptic neurons. Without a functional reuptake pump, serotonin (5-hydroxytryptamine [5-HT]) is not broken down or
recycled to produce more 5-HT. Instead, there will be an accumulation of this particular neurotransmitter in the synaptic cleft for continuous stimulation of serotonergic neurons.
However, this process has no correlation to the duration of
therapy since the onset of action for all antidepressants is
typically delayed. If this were the case, adolescents would
feel immediate relief within three days. Typically, maximum
improvement in mood can take place within two weeks.19
Another mechanism suggests that SSR!s induce desensitization of somatodendritic and terminal 5-HTlA autoreceptors,
proteins responsible in inhibiting the release of 5-HT and
other neurotransmitters from the presynaptic neuron.20
Overstimulation of the autoreceptors would cause this desensitization. By attenuating the negative feedback responsibilities of these autoreceptors, 5-HT will accumulate to a
greater extent, leading to an antidepressant response.
Side effects associated with SSRI use occur due to the inhibition of other signaling transduction pathways; thus, leading
to additional physiological responses.20 Selective serotonin
reuptake inhibitors generally improve mood, but they can
also cause one to experience suicidal thoughts due to the
inhibition of dopamine neurotransmission. Increasing concentrations of 5-HT with SSR!s downregulates dopamine
receptors in the prefrontal cortex, the area of the brain responsible for cognitive behavior, personality, expression,
decision-making and moderating social behavior.20 Compromising mesocortical dopaminergic pathways could trigger
impulsive and aggressive behavior toward oneself (e.g. suicide). To reverse the downregulation of dopamine receptors,
researchers are currently investigating 5-HT2c receptors,
proteins localized in the dorsal striatum, which are responsi-
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ble for modulating striatal and prefrontocortical dopamine
concentrations.20 By discovering the correlation between
these receptors and dopaminergic tone, scientists can better
treat conditions such as depression.

ily history of suicide. The AACAP supports the FDA recommendation that patients be seen once a week for the first
four weeks of therapy and then biweekly thereafter. Monitoring can be done via telephone or by a face-to-face meeting.a

Black Box Warning
In 2004, the FDA directed all manufacturers of antidepressants to add a black box warning (BBW) to SSRI labeling to
alert health care providers of the increased risk of suicidality
in children and adolescents being treated with these agents.
The FDA also directed manufacturers to include information
from pediatric studies regarding suicide risk in the labeling. 21
While suicide risk is highlighted for children, adolescents,
and young adults, labeling states that all patients taking antidepressants should be monitored for clinical worsening, suicidality, or altered behavior during the initial months of
treatment and during any dosage changes. 22·23 According to
the warnings, the clinical need of the medication should be
weighed against the clinical risks in any child, adolescent or
young adult patient who is being considered for antidepressant therapy.21

SSRI-Resistant Depression
Some adolescent patients may not see any improvement after initial treatment with an SSRI. The National Institute of
Mental Health funded a multi-site, clinical study to investigate treatment of adolescents with SSRI-resistant depression
(TORDIA) that was conducted from 2000-2006.27 The purpose of the study was to evaluate the efficacy of four different treatment strategies in adolescents who did not respond
to initial treatment with an SSRI. Three hundred and thirtyfour adolescents, ages 12 to 18 years, who had not responded to two months of initial treatment were randomized
to one of the four treatment groups. Treatment groups included: switch to an alternate SSRI, switch to the selective
serotonin-norepinephrine reuptake inhibitor (SSNRI) venlafaxine, switch to a new SSRI in combination with CBT, and
switch to venlafaxine in combination with CBT. The groups
treated with both venlafaxine and CBT or a new SSRI in combination with CBT had a higher rate of clinical response than
the groups that did not incorporate CBT. There was no difference in clinical response between the adolescents who
switched to a new SSRJ and the adolescents who were
treated with venlafaxine. However, venlafaxine was associated with a greater increase in diastolic blood pressure, pulse
rate and skin problems. The TORDIA study was designed to
detect a 10 percent difference between groups at a power of
80 percent for a sample size of 400 participants. Brent and
colleagues stated that the sample size was not met due to a
public health advisory that the FDA issued to health care providers regarding risk of suicidality in pediatric patients taking SSRls. The warning was issued at the midpoint of the
study in 2003. The authors noted that recruitment of participants became difficult when the concern about suicide risk in
pediatric patients taking SSRis increased; thus, the overall
use of SSR!s declined.2 7,2a Although the results were not statistically significant, TORDIA still provided clinically significant data regarding treatment options for adolescents who
do not respond to initial SSRI treatment.

Controversy still exists over this BBW. Some studies have
shown statistically significant increases in suicidal thoughts
and actions in adolescents on SSR!s, while others have
not.24,25,26 A study by Gibbons and colleagues showed that
adolescent patients on SSRis had a lower risk of suicide compared to patients on placebo.26 Additionally, the governmentfunded Treatment for Adolescents with Depression Study
(TADS) found that patients who received combination therapy of medications and psychotherapy had a lower suicide
risk.24 Interestingly, early in the trial, 29 percent of patients
had suicidal thoughts. At the end of the study only 8 percent
of patients on combination therapy had suicidal thoughts,
compared to 15 percent of patients taking fluoxetine alone.24
In another study, Ma and fellow researchers found that while
the number of prescriptions for antidepressants is increasing, fewer patients are receiving them in combination with
psychotherapy. 2s The AACAP recommends adolescents receive both medication and psychotherapy. This treatment
combination is beneficial because it provides an opportunity
for patients to develop coping skills and helps them develop
a plan to continue treatment. The decrease in psychotherapy
utilization may be a confounding factor contributing to the
increased suicide rate associated with SSR!s.s
Some practitioners argue that the BBW discourages doctors
from prescribing antidepressants to adolescents who really
need to be treated with medication. Others argue that the
risk of suicide, if MDD is left untreated, is higher than if a patient was placed on an SSRI. Regardless of reasoning, there is
need for more research to discover whether or not suicidal
activity is definitively linked to SSRI use in adolescents.23
Because a warning exists, the AACAP suggests that all patients receiving SSRis be monitored for suicidal thoughts and
actions. Patients with an especially high risk of suicide
should be monitored particularly closely. These patients include those sufferii:ig from bipolar disorder, substance abuse,
sexual abuse and patients with suicidal tendencies or a famJune 2014 Volume 5, Issue 2

Special Considerations with Antidepressant Treatment
in Adolescents
There is high variability in adolescent placebo response,
which limits interpretation of clinical trials for pharmacologic treatment of adolescents with MDD. Trials comparing
antidepressant treatment to placebo in adolescents have reported a wide range of placebo response from lower rates of
approximately 20 percent to higher rates of 70 percent.29-32
Variable placebo response to antidepressants is not restricted to the adolescent population. Reif and colleagues
recently conducted a meta-analysis analyzing 96 studies and
9,566 patients (excluding children). The analysis did not differentiate between different classes of antidepressants. In
patients taking antidepressants versus placebo, it was determined that the placebo response accounted for 68 percent of
the effect in the drug groups. However, variations in the depression diagnosis (i.e. type and severity) and study design
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were noted as cause for variation in recorded placebo responses.33 Therefore, in future research, the effect of placebo
treatment in depressed adolescents will be a necessary consideration. It is important to note that research regarding
pediatric patients is often limited by small sample sizes due
to fear of complications or violation of ethical standards.
Another important consideration in pharmacologic treatment is the developmental differences between adolescents
and adults that can impact various pharmacokinetic parameters. In practice, pediatric dosing is often derived from the
adult dose and adjusted according to body weight or body
surface area for off-label uses of medications. Because this
method does not account for developmental differences, it
places patients at risk for either sub-therapeutic dosing and
lack of effect or supra-therapeutic dosing and adverse
events.3 4 According to a systematic review conducted by Moreno and colleagues, adolescents may, theoretically, experience higher plasma concentrations of lipophilic drugs like
antidepressants and antipsychotics because they have a
higher body water/adipose ratio (i.e. lower percentage of
body fat) than adults.JS However, it is also believed that hepatic cytochromes have higher activity in adolescents around
puberty than adults. Once puberty is reached, sex hormones
are believed to compete for hepatic enzymes, meaning higher
doses of antidepressants may be required to avoid subtherapeutic dosing.3s
Adolescents qualifying for discontinuation of therapy that
are currently taking SSR!s or SSNRls must be gradually
weaned off their medications over a four-week time period.36
Patients who are suddenly taken off their medications can
experience discontinuation symptoms. The symptoms are
characterized by a severe withdrawal effect resulting in
headaches, nausea, tremor, anxiety and agitation. Research
has indicated that the magnitude of withdrawal is inversely
proportional to the half-life of the drug.36 A shorter half-life
would result in a faster elimination rate and more episodes
of discontinuation symptoms. Fluoxetine, which has a very
long half-life (one to three days after acute administration
and four to six days after chronic administration), evokes the
least amount of withdrawal symptoms for patients. On the
contrary, other SSRis (i.e paroxetine and sertraline) and
SSNRls (i.e venlafaxine, duloxetine) evoke more severe withdrawal symptoms.36.37 Venlafaxine, with a short
half-life of three to 13 hours, is rarely indicated for adolescents with depressive disorders because it tends to cause
more frequent and robust withdrawal symptoms. In the literature, SSNRls have not demonstrated better effectiveness
than SSRls.36 Additionally, since they cause more adverse
reactions than SSRls, SSNRis should be avoided and not recommended as first-line agents in adolescent patients with
depressive disorders.

Thoughts on Adolescent Depression
In 2003, the American Psychological Association (APA) issued a press release stating that adolescents who suffer from
depression are susceptible to relapses of symptoms in adulthood. According to APA, intervention and prevention of adolescent depression are important to avoid such relapses.3B

36

In 2005, the National Institute for Health and Clinical Excellence (NICE) and the National Collaborating Centre for Mental Health issued a press release stating that new standards
had been developed regarding the treatment of depression in
adolescents. According to NICE, mild depression should not
be treated with antidepressants, and psychological therapy
should be first-line treatment for moderate to severe depression. If antidepressant therapy is initiated, it should be
provided along with psychological therapy. Health care professionals in close contact with adolescents should be trained
to detect symptoms of depression. The standards also mentioned that there is the possibility of concurrent depression
in parents that would need to be addressed in order to ensure effective treatment of their child's depression.39
In 2006, APA issued a press release highlighting a report regarding the gap in care for many adolescents. The gap was
associated with limited access to appropriate services for
mental health issues. The report called for research to further investigate the efficacy of treatments for depression as
well as what doses and dosage intervals are appropriate in
the adolescent population. The need for further research in
the various combinations of pharmacologic treatment and
psychotherapy was also highlighted. The American Psychological Association's report stressed the importance for research to investigate the role of outside influences such as
family members or school employees on depressed adolescents' adherence to treatment. Additionally, APA cited a need
for increased collaboration among U.S. federal agencies that
fund treatment research as well as public disclosure of safety
and efficacy data from the treatment research.40

The Pharmacists' Role
Pharmacists have an important role in monitoring patient
compliance and safety with antidepressant medications. It is
imperative to inform patients to not abruptly discontinue
their therapy. Adolescents and their parents should be informed of the aforementioned risks due to sudden discontinuation (i.e withdrawal symptoms). Discontinuation could
result in a longer duration of therapy to not only correct the
withdrawal symptoms, but to also treat the original depression state. Patients and their caregivers should also be advised that the physician will make all necessary medication
adjustments as needed. Modifying medication therapy by
oneself should be strictly prohibited; instead, one must consult with the physician. Since adolescents typically have
faster metabolism than adults, they can experience even
more severe withdrawal symptoms.36 However, these effects
and risks can be avoided with appropriate clinical management.
Pharmacists can also play an important role in providing
nonpharmacologic counseling to adolescents experiencing
recurrent episodes of suicidal ideation by encouraging patients and/or their parents to attend regular psychotherapy
sessions. Furthermore, it is imperntive to look for any signs
of bipolar disorder, schizophrenia and/or a history of MOD in
family members via examining family health history. The
pharmacist should work collaboratively with the primary
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physician to get any health information needed. If a family
history of mental health disorders exists, then this may be a
contributing factor to the patient's depression. Explaining
this possible genetic link to patients could help to further the
patient's understanding of their disease. Additionally, patient
noncompliance of medication therapy is an area where pharmacists can make very positive interventions. Patient noncompliance can be due not only to lack of understanding
about the importance of taking these antidepressants on a
regular basis, but also can be due to the possible side effects
from antidepressants. Thus, face-to-face follow-up visits with
the pharmacist should be highly encouraged. These visits
could occur weekly or biweekly. Seeing both a pharmacist as
well as a physician could help to ensure efficacy and decrease
the risk of adverse effects of antidepressant medications. It is
imperative to also counsel parents about the importance of
compliance with antidepressant medications, since caregivers/parents have great influence on an adolescent's life.
Upon dispensing medications, pharmacists should also distribute medication guides, so that the patient can be fully
aware as to what their therapy entails, and encourage the
patient to call with any questions or concerns.41

Conclusion
Although guidelines exist for the treatment of MOD in adolescents, these reports vary and are oftentimes not utilized in
clinical practice. Treatment is inconsistent among physicians,
and prescribers often choose to prescribe medications that
are not indicated for the treatment of MOD in adolescents.
More research needs to be conducted to further clarify the
guidelines, add additional therapies to treatment options and
to end the controversy that exists over whether or not to
treat adolescent MOD patients with fluoxetine or escitalopram. Increasing the amount of patient and parent counseling will hopefully lessen the fear of adverse effects and social
stigma concerns that surround antidepressants, allowing
adolescents to receive the treatment that they need for
MDo.20 There are risks and benefits with taking medications
to treat MOD; however, the benefits more often outweigh the
risks. Effectiveness of medications can be achieved if dosing
is gradually titrated, assuming that the patient is responding
well to therapy. Most importantly, patients should avoid
high-risk agents such as SSNRis.41 Finally, it is important for
health care providers to communicate with one another and
with their patients to address these risks and benefits for
antidepressant treatment in adolescents. Due to their accessibility, pharmacists play a particularly important role in
educating patients and caregivers on the importance of
medication adherence and monitoring for signs of suicidal
ideation.
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